ralimetinib

structure in first source

Also Known As:

3-(2,2-Dimethylpropyl)-5-(4-(4-fluorophenyl)-2-(2-methyl-2-propanyl)-1H-imidazol-5-yl)-3H-imidazo(4,5-b)pyridin-2-amine; 3H-Imidazo(4,5-b)pyridin-2-amine, 5-(2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl)-3-(2,2-dimethylpropyl)-; LY2228820; LY2228820 dimesylate

Networked: 12 relevant articles (1 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Imidazoles: 150
      - ralimetinib: 12
  - Pyridines: 88
    - ralimetinib: 12

Experts

1.	Farrington, Daphne L: 3 articles (01/2020 - 03/2016)
2.	Pitou, Celine: 3 articles (01/2020 - 03/2016)
3.	Bell, Robert: 2 articles (01/2020 - 03/2016)
4.	Bell-McGuinn, Katherine: 2 articles (01/2020 - 01/2020)
5.	Campbell, Robert: 2 articles (01/2020 - 01/2020)
6.	Chan, Edward M: 2 articles (03/2016 - 02/2014)
7.	Stancato, Louis F: 2 articles (03/2016 - 02/2014)
8.	Campbell, Robert M: 2 articles (02/2014 - 05/2008)
9.	Shih, Chuan: 2 articles (02/2014 - 05/2008)
10.	Starling, James J: 2 articles (02/2014 - 05/2008)

Related Diseases

1.	Ovarian Epithelial Carcinoma 01/01/2020 - "This phase 1b/2 clinical trial (NCT01663857) evaluated the efficacy of ralimetinib in combination with gemcitabine (G) and carboplatin (C), followed by maintenance ralimetinib, for patients with recurrent platinum-sensitive epithelial ovarian cancer. "
2.	Neoplasms (Cancer) 01/01/2019 - "Mechanistic studies showed that LY2228820 sensitized cancer cells to AMT agents independent of P-gp. " 01/01/2019 - "This P-gp-independent regime containing LY2228820 and AMT agents could produce synergistic anti-cancer effects without extra systematic toxicity. " 01/01/2019 - "Furthermore, LY2228820 blocked the p-HSP27 mediated protective response against AMT drugs in tumor cells, resulting in mitochondrial instability and the activation of mitochondrial death pathways. " 01/01/2019 - "In drug-resistant cancer cells, treatment with either LY2228820 or AMT drug alone was compatible with viability, while co-administration of both led to dramatic cytotoxicity, G2/M arrest and apoptosis. " 03/01/2016 - "Ralimetinib demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer."
3.	Ovarian Neoplasms (Ovarian Cancer) 01/01/2020 - "A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer."
4.	Glioblastoma (Glioblastoma Multiforme) 01/01/2021 - "This phase 1 trial is the first trial to study the combination of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. " 01/01/2021 - "This phase 1 trial aimed to determine the maximum tolerated dose (MTD; primary objective) of a p38-MAPK inhibitor, ralimetinib, with radiotherapy (RT) and chemotherapy (TMZ), in the treatment of newly diagnosed glioblastoma (GBM) patients. " 01/01/2021 - "Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma."
5.	Melanoma (Melanoma, Malignant) 02/01/2014 - "In mice transplanted with B16-F10 melanoma, tumor phospho-MK2 (p-MK2) was inhibited by LY2228820 in a dose-dependent manner [threshold effective dose (TED)(70) = 11.2 mg/kg]. " 10/30/2015 - "In this work, we show that p38 inhibition using SB202190 or LY2228820 potently suppressed DKK-1 expression by MDA-231 and MCF-7 breast cancer cell lines as well melanoma derived MDA-435 cells. " 02/01/2014 - "LY2228820 produced significant tumor growth delay in multiple in vivo cancer models (melanoma, non-small cell lung cancer, ovarian, glioma, myeloma, breast). "

Related Drugs and Biologics

1.	Carboplatin (JM8)
2.	Platinum
3.	Gemcitabine
4.	ralimetinib
5.	p38 Mitogen-Activated Protein Kinases
6.	Tamoxifen
7.	Temozolomide (Temodar)
8.	Checkpoint Kinase 1
9.	prexasertib
10.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Radiotherapy